Article info
Clinical and epidemiological research
Extended report
Inflammatory arthritis and sicca syndrome induced by nivolumab and ipilimumab
- Correspondence to Dr Laura C Cappelli, Division of Rheumatology, Department of Medicine, Johns Hopkins University, 5200 Eastern Avenue, MFL Center Tower 4100, Baltimore, MD 21224, USA; lcappel1{at}jhmi.edu
Citation
Inflammatory arthritis and sicca syndrome induced by nivolumab and ipilimumab
Publication history
- Received March 22, 2016
- Revised May 16, 2016
- Accepted May 27, 2016
- First published June 15, 2016.
Online issue publication
November 02, 2019
Article Versions
- Previous version (2 November 2019).
- Previous version (2 November 2019).
- You are viewing the most recent version of this article.
Lay summary
This web only file has been produced by the BMJ Publishing Group from an electronic file supplied by the author(s) and has not been edited for content.
Request permissions
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.
Copyright information
Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://www.bmj.com/company/products-services/rights-and-licensing/